Company profile
Alzamend Neuro, Inc.
NASDAQ:ALZNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LATOZINEMAB | phase1_2 | — | 7 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06921590 | phase1 | completed | 2025-05-09 | 2025-12-15 | Alzamend Neuro, Inc. | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects |
| NCT07540338 | phase1_2 | recruiting | 2026-05-11 | 2026-12-01 | Alzamend Neuro, Inc. | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder |
| NCT05363293 | phase1_2 | completed | 2022-05-04 | 2023-04-14 | Alzamend Neuro, Inc. | Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects |
| NCT05834296 | phase1_2 | active_not_recruiting | 2023-07-05 | 2028-03-03 | Alzamend Neuro, Inc. | Study in Subjects With Mild-to-Moderate Alzheimer's Dementia |
FDA applications (0)
No records yet.